NEW YORK (GenomeWeb) – Newly publicly traded cancer molecular diagnostics firm Signal Genetics today said that the New York State Department of Health has approved the Myeloma Prognostic Risk Signature test, making it available in all 50 states in the US.
Signal is making the test available in the state immediately. More than 24,000 multiple myeloma patients in the country now have access to MyPRS as a result of the approval. MyPRS is a microarray-based gene expression profiling assay that predicts the risk of early relapse and enables physicians to stratify their patients and treatment options and to identify genomic alterations that may affect the choice of therapies.
Signal went public about two weeks ago with its shares trading on the Nasdaq.